RCUS
Price:
$25.26
Market Cap:
$2.73B
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic can...[Read more]
Industry
Biotechnology
IPO Date
2018-03-15
Stock Exchange
NYSE
Ticker
RCUS
According to Arcus Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.59B. This represents a change of 162.10% compared to the average of 987.23M of the last 4 quarters.
The mean historical Enterprise Value of Arcus Biosciences, Inc. over the last ten years is 1.04B. The current 2.59B Enterprise Value has changed 24.81% with respect to the historical average. Over the past ten years (40 quarters), RCUS's Enterprise Value was at its highest in in the December 2021 quarter at 2.82B. The Enterprise Value was at its lowest in in the March 2018 quarter at -51615845.12.
Average
1.04B
Median
1.25B
Minimum
301.77M
Maximum
2.78B
Discovering the peaks and valleys of Arcus Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 228.59%
Maximum Annual Enterprise Value = 2.78B
Minimum Annual Increase = -49.45%
Minimum Annual Enterprise Value = 301.77M
| Year | Enterprise Value | Change |
|---|---|---|
| 2024 | 1.25B | -3.53% |
| 2023 | 1.30B | -7.52% |
| 2022 | 1.40B | -49.45% |
| 2021 | 2.78B | 119.55% |
| 2020 | 1.26B | 228.59% |
| 2019 | 384.71M | 27.48% |
| 2018 | 301.77M | -5.40% |
| 2017 | 319.00M | -9.44% |
The current Enterprise Value of Arcus Biosciences, Inc. (RCUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.32B
5-year avg
1.60B
10-year avg
1.04B
Arcus Biosciences, Inc.’s Enterprise Value is greater than ImmunityBio, Inc. (2.24B), less than Denali Therapeutics Inc. (2.90B), greater than Galapagos N.V. (1.73B), less than Cogent Biosciences, Inc. (5.53B), greater than 89bio, Inc. (2.11B), greater than Agios Pharmaceuticals, Inc. (1.55B), greater than Viridian Therapeutics, Inc. (2.54B), less than Beam Therapeutics Inc. (2.82B), greater than Ocular Therapeutix, Inc. (1.89B), less than Liquidia Corporation (2.94B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 2.24B | $2.26B | |
| 2.90B | $2.95B | |
| 1.73B | $2.09B | |
| 5.53B | $5.60B | |
| 2.11B | $2.20B | |
| 1.55B | $1.60B | |
| 2.54B | $2.64B | |
| 2.82B | $2.93B | |
| 1.89B | $2.16B | |
| 2.94B | $2.90B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arcus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arcus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Arcus Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
What is the 3-year average Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
What is the 5-year average Enterprise Value for Arcus Biosciences, Inc. (RCUS)?
How does the current Enterprise Value for Arcus Biosciences, Inc. (RCUS) compare to its historical average?